A framework for setting enrollment goals to ensure participant diversity in sponsored clinical trials in the United States.

Autor: Cullen MR; Department of Medicine, Biomedical Data Science and Health Policy, Stanford University, Stanford, CA, USA., Lemeshow AR; Pfizer Inc., NY, USA., Amaro S; Pfizer Inc., NY, USA., Bandera EV; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Cooper LA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kawachi I; Department of Social Epidemiology, Harvard University, Cambridge, MA, USA., Lunyera J; Division of General Internal Medicine, Department of Medicine, Duke University, Durham, NC, USA., McKinley L; Pfizer Inc., NY, USA., Poss CS; Pfizer Inc., NY, USA., Rottas MM; Pfizer Inc., NY, USA., Schachterle SE; Pfizer Inc., NY, USA., Thadeio PF; Pfizer Inc., NY, USA., Russo LJ; Pfizer Inc., NY, USA. Electronic address: leo.j.russo@pfizer.com.

Publikováno v: Contemporary clinical trials [Contemp Clin Trials] 2023 Jun; Vol. 129, pp. 107184. Date of Electronic Publication: 2023 Apr 11.